share_log

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%), etc.

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%), etc.

T2 Biosystems | SC 13D/A：超过5%持股股东披露文件(修正)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%)等
美股sec公告 ·  05/07 19:51
Moomoo AI 已提取核心信息
In a recent filing with the United States Securities and Exchange Commission, Nathan D. Hukill, along with associated entities including CR Group L.P. and various CRG Partners funds, reported a significant change in their beneficial ownership of T2 Biosystems, Inc. The group now collectively owns 8,853,173 shares, representing approximately 65.4% of the company's issued and outstanding common stock. This change in ownership is a result of the cancellation of outstanding loans to T2 Biosystems by the reporting entities, as detailed in the amended Schedule 13D filed on May 7, 2024. The loans were originally part of a Term Loan Agreement dated December 30, 2016. The most recent acquisitions of shares by the group occurred on April 12 and May 3, 2024. The filing indicates that no other transactions in the common stock have been made by the reporting persons in the last 60 days.
In a recent filing with the United States Securities and Exchange Commission, Nathan D. Hukill, along with associated entities including CR Group L.P. and various CRG Partners funds, reported a significant change in their beneficial ownership of T2 Biosystems, Inc. The group now collectively owns 8,853,173 shares, representing approximately 65.4% of the company's issued and outstanding common stock. This change in ownership is a result of the cancellation of outstanding loans to T2 Biosystems by the reporting entities, as detailed in the amended Schedule 13D filed on May 7, 2024. The loans were originally part of a Term Loan Agreement dated December 30, 2016. The most recent acquisitions of shares by the group occurred on April 12 and May 3, 2024. The filing indicates that no other transactions in the common stock have been made by the reporting persons in the last 60 days.
在最近向美国证券交易委员会提交的一份文件中，内森·哈基尔以及包括CR集团有限责任公司和各种CRG Partners基金在内的关联实体报告说，他们对T2 Biosystems, Inc.的实益所有权发生了重大变化。该集团现在共拥有8,853,173股股票，约占该公司已发行和流通普通股的65.4％。所有权变更是申报实体取消了对T2 Biosystems的未偿贷款的结果，详情见2024年5月7日提交的经修订的附表13D。这些贷款最初是2016年12月30日定期贷款协议的一部分。该集团最近一次的股票收购发生在2024年4月12日和5月3日。该文件显示，在过去的60天中，申报人没有进行任何其他普通股交易。
在最近向美国证券交易委员会提交的一份文件中，内森·哈基尔以及包括CR集团有限责任公司和各种CRG Partners基金在内的关联实体报告说，他们对T2 Biosystems, Inc.的实益所有权发生了重大变化。该集团现在共拥有8,853,173股股票，约占该公司已发行和流通普通股的65.4％。所有权变更是申报实体取消了对T2 Biosystems的未偿贷款的结果，详情见2024年5月7日提交的经修订的附表13D。这些贷款最初是2016年12月30日定期贷款协议的一部分。该集团最近一次的股票收购发生在2024年4月12日和5月3日。该文件显示，在过去的60天中，申报人没有进行任何其他普通股交易。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息